The 82x ROI Claim Looks Great on a Slide Deck — But Who’s Paying for the Infrastructure at the Site?
Tufts CSDD says AI monitoring agents deliver 82x ROI in Phase 3 oncology. But that number assumes sites can...
Tufts CSDD says AI monitoring agents deliver 82x ROI in Phase 3 oncology. But that number assumes sites can...
Scholar Rock's BLA refiling for SMA drug apitegromab after Catalent Indiana's OAI classification shows how CMO inspection failures translate...
ICON's multi-year Claude deployment will reshape eTMF workflows, protocol timelines, and site data ops. Here's what coordinators need to...
ICON's Anthropic partnership deploys Claude into clinical trial monitoring. Here's what site coordinators and ops leads need to verify...
ICON's Anthropic partnership deploys Claude AI into clinical trials. Here's what it means for EDC workflows, IRB docs, and...
Lancet Neurology data shows <4% of Parkinson's genetic trials enroll non-European patients. Here's what ops teams must fix before...
Acrosian's AI-native CRO launch forces a real question: can legacy biometrics vendors support DCT-era data demands, or is your...
A landmark Lancet Neurology study exposes the operational gap in Parkinson's trials: ancestry-based biomarker screening built for European cohorts...
A 99,783-person multi-ancestry Parkinson's study just exposed a critical enrollment gap: GBA1 and LRRK2 trials run almost exclusively in...
Alembic's July 2026 FDA warning letter on informed consent failures at its Vadodara BE facility exposes the GCP documentation...